Avidity Partners Management’s Janux Therapeutics JANX Stock Holding History

Avidity Partners Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-258,000	Closed	-$6.97M	–	72
2025 Q1	$6.97M	Sell	258,000 -483,900	-65%	-$18.2M	1.33%	33
2024 Q4	$39.7M	Buy	741,900 +179,900	+32%	+$9.52M	3.9%	3
2024 Q3	$25.5M	Sell	562,000 -278,219	-33%	-$12.1M	1.3%	32
2024 Q2	$35.2M	Buy	840,219 +455,974	+119%	+$21.4M	1.5%	25
2024 Q1	$14.5M	Buy	+384,245	New	+$8.37M	0.47%	58

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Avidity Partners Management's JANX Position: Q2 2025 in Review

Avidity Partners Management sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 258,000 shares — an estimated $6.97M sold.

Avidity Partners Management first reported a position in JANX in Q1 2024 and held it in 5 quarters. The position peaked at $39.7M in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

Avidity Partners Management reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
Avidity Partners Management sold 258,000 Janux Therapeutics shares in Q2 2025, an estimated $6.97M.
Avidity Partners Management first reported a position in Janux Therapeutics in Q1 2024 and held it in 5 quarters.
Avidity Partners Management's Janux Therapeutics position peaked at $39.7M in Q4 2024.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.